GlaxoSmithKline Plc - Product Pipeline Review - 2016

Date: February 29, 2016
Pages: 406
Price:
US$ 1,500.00 US$ 1,275.00
Offer valid until December 31, 2016!
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: G2F3A961EA9EN
Leaflet:

Download PDF Leaflet

GlaxoSmithKline Plc - Product Pipeline Review - 2016

Summary

Global Markets Direct’s, ‘GlaxoSmithKline Plc - Product Pipeline Review - 2016’, provides an overview of the GlaxoSmithKline Plc’s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by GlaxoSmithKline Plc, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope
  • The report provides a snapshot of the pipeline therapeutic landscape of GlaxoSmithKline Plc
  • The report provides overview of GlaxoSmithKline Plc including its business description, key facts, and locations and subsidiaries
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report assesses GlaxoSmithKline Plc’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report features GlaxoSmithKline Plc’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects
Reasons to buy
  • Evaluate GlaxoSmithKline Plc’s strategic position with total access to detailed information on its product pipeline
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for GlaxoSmithKline Plc
  • Identify potential new clients or partners in the target demographic
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding GlaxoSmithKline Plc’s pipeline depth and focus of pipeline therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
GlaxoSmithKline Plc Snapshot
GlaxoSmithKline Plc Overview
Key Information
Key Facts
GlaxoSmithKline Plc - Research and Development Overview
Key Therapeutic Areas
GlaxoSmithKline Plc - Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products - Monotherapy
Pipeline Products - Combination Treatment Modalities
Pipeline Products - Partnered Products
Pipeline Products - Out-Licensed Products
GlaxoSmithKline Plc - Pipeline Products Glance
GlaxoSmithKline Plc - Late Stage Pipeline Products
GlaxoSmithKline Plc - Clinical Stage Pipeline Products
GlaxoSmithKline Plc - Early Stage Pipeline Products
GlaxoSmithKline Plc - Unknown Stage Pipeline Products
GlaxoSmithKline Plc - Drug Profiles
gepirone hydrochloride ER

GSK-257049


GSK-2696273

mepolizumab
melanoma lysate vaccine
(fluticasone furoate + umeclidinium bromide + vilanterol trifenatate)
(fluticasone furoate + vilanterol trifenatate)
(measles [strain Schwarz] + mumps [strain RIT 4385] + rubella [strain Wistar RA 27/3]) vaccine
albiglutide
ambrisentan
AS15 + recMAGE-A3
belimumab
bupropion hydrochloride ER
Ebola [Zaire] vaccine
fluticasone furoate

GSK-1437173A

inotersen sodium

KD-295

losmapimod
meningococcal [serotype B] vaccine
retosiban
tafenoquine succinate
vilanterol trifenatate
zanamivir
(batefenterol succinate + fluticasone furoate)
(fluticasone furoate + levocabastine hydrochloride)
alitretinoin
batefenterol

CAD-106

camicinal
dabrafenib mesylate + panitumumab + trametinib dimethyl sulfoxide
danirixin
daprodustat
fluticasone furoate + umeclidinium bromide
gepotidacin mesylate
group B Streptococcus (trivalent) vaccine

GSK-2189242A


GSK-2231392A


GSK-2245035


GSK-2256098


GSK-2269557


GSK-2302032A


GSK-2315698 + GSK-2398852


GSK-2330672


GSK-2339345


GSK-239512


GSK-2586881


GSK-2696274


GSK-2696275


GSK-2789869A


GSK-2830930A


GSK-2838504A


GSK-2862277


GSK-3003891A


GSK-3196165


GSK-3277511A


GSK-692342


GSK-933776


GVXNSD-133

hepatitis C vaccine
malaria vaccine
mapatumumab
maribavir
meningococcal [serotypes A, B, C, W-135, Y] (pentavalent) vaccine
otelixizumab
respiratory syncytial virus vaccine
rilapladib
Streptococcal pneumonia vaccine
umeclidinium bromide

GSK-2302025A


GSK-2636771


GSK-525762

HIV [strains C1086 + TV1] (bivalent) vaccine
pazopanib hydrochloride + pembrolizumab

TDEN-PIV

(amlodipine besylate + rosuvastatin calcium)
(candesartan cilexetil + hydrochlorothiazide)
(diphtheria + pertussis (acellular) + tetanus) vaccine

1790GAHB

EcoXyn-4V
epelsiban besylate

FP-1039


GSK-1940029


GSK-2130579A


GSK-2241658A


GSK-2256294


GSK-2330811


GSK-2618960


GSK-2646264


GSK-2654909A


GSK-2654911A


GSK-2789868A


GSK-2798745


GSK-2800528


GSK-2816126


GSK-2831781


GSK-2849330


GSK-2857916


GSK-2878175


GSK-2879552


GSK-2881078


GSK-2981278


GSK-2981710


GSK-2982772


GSK-3008348


GSK-3117391


GSK-3174998


GSK-3206640A


GSK-3206641A


GSK-3389245A

hepatitis C vaccine
HIV vaccine
HIV vaccine

IMP-731

influenza [strain A/H5N1] vaccine
influenza vaccine
montelukast sodium
omipalisib
oxytocin

RSV-001

Staphylococcus aureus vaccine
meningococcal [serotypes A, C, W-135, Y] (tetravalent) vaccine
BLyS-gel
Cellular Immunotherapy to Target Flt3L for Autoimmune Myocarditis
Gene Therapy to Activate Lysyl Hydroxylase-3 for Recessive Dystrophic Epidermolysis Bullosa

GSK-030


GSK-1795091


GSK-2041706


GSK-214096


GSK-2225745


GSK-2394002


GSK-2656157


GSK-2795039


GSK-2820151


GSK-3039294


GSK-3277509A


GSK-3277510A


GSK-3326595


GSK-3359609


GSK-6288B


GSK-8853


GSKJ-4


GW-610742

HIV vaccine
influenza vaccine
marburg vaccine
meningococcal vaccine
Monoclonal Antibody Conjugate for Oncology
raxibacumab
Recombinant Protein to Antagonize CCR8 for Graft Versus Host Disease and Multiple Sclerosis
Small Molecule 1 for Malaria
Small Molecule 1 to Inhibit Histone Methyltransferases for Cancer
Small Molecule 2 for Malaria
Small Molecule 2 for Tuberculosis
Small Molecule 2 to Inhibit Histone Methyltransferases for Cancer
Small Molecule 3 to Inhibit Histone Methyltransferases for Cancer
Small Molecule for Hypertension and Insulin Resistance
Small Molecule to Activate AMPK for Type 2 Diabetes
Small Molecule to Agonize S1P1 for Multiple Sclerosis
Small Molecules to Inhibit InhA for Tuberculosis
Small Molecules to Inhibit ROR gamma-t for Multiple Sclerosis and Rheumatoid Arthritis
staphylococci aureus vaccine
Streptococcal pneumonia vaccine

TC-2153

tuberculosis vaccine
Vaccine for Alzheimer's Disease
Vaccine for Cancer
bacterial vaccine
bacterial vaccine
Drug for Chronic Liver Disease
Drugs to Antagonize T-Cell Receptor for Oncology
Drugs to Inhibit Kynurenine 3-Monooxygenase for Acute Pancreatitis

GSK-137647A


GSK-343


GSK-5959


GSKJ-1

Proteins for Musculoskeletal Disorders
Pseudomonas aeruginosa vaccine
Small Molecule for Tuberculosis
Small Molecule to Antagonize FFA4 for Undisclosed Indication
Small Molecule to Inhibit Histone Deacetylases for Oncology
Small Molecules for HIV-1 Infection
Small Molecules for Tuberculosis
Small Molecules for Undisclosed Indication
Small Molecules to Antagonize Folate Receptor for Tuberculosis
Small Molecules to Inhibit ATPase family AAA Domain-Containing Protein 2 for Oncology
Small Molecules to Inhibit Falcipain for Malaria
Small Molecules to Inhibit Leucyl-tRNA Synthetase for Tuberculosis
Small Molecules to Inhibit RNA Polymerase for Hepatitis C
(paratyphoid + typhoid) vaccine
GlaxoSmithKline Plc - Pipeline Analysis
GlaxoSmithKline Plc - Pipeline Products by Target
GlaxoSmithKline Plc - Pipeline Products by Route of Administration
GlaxoSmithKline Plc - Pipeline Products by Molecule Type
GlaxoSmithKline Plc - Pipeline Products by Mechanism of Action
GlaxoSmithKline Plc - Recent Pipeline Updates
GlaxoSmithKline Plc - Dormant Projects
GlaxoSmithKline Plc - Discontinued Pipeline Products
Discontinued Pipeline Product Profiles
GlaxoSmithKline Plc - Company Statement
GlaxoSmithKline Plc - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
GlaxoSmithKline Plc - Key Manufacturing Facilities
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

GlaxoSmithKline Plc, Key Information
GlaxoSmithKline Plc, Key Facts
GlaxoSmithKline Plc - Pipeline by Indication, 2016
GlaxoSmithKline Plc - Pipeline by Stage of Development, 2016
GlaxoSmithKline Plc - Monotherapy Products in Pipeline, 2016
GlaxoSmithKline Plc - Combination Treatment Modalities in Pipeline, 2016
GlaxoSmithKline Plc - Partnered Products in Pipeline, 2016
GlaxoSmithKline Plc - Partnered Products/ Combination Treatment Modalities, 2016
GlaxoSmithKline Plc - Out-Licensed Products in Pipeline, 2016
GlaxoSmithKline Plc - Out-Licensed Products/ Combination Treatment Modalities, 2016
GlaxoSmithKline Plc - Pre-Registration, 2016
GlaxoSmithKline Plc - Filing rejected/Withdrawn, 2016
GlaxoSmithKline Plc - Phase III, 2016
GlaxoSmithKline Plc - Phase II, 2016
GlaxoSmithKline Plc - Phase I, 2016
GlaxoSmithKline Plc - IND/CTA Filed, 2016
GlaxoSmithKline Plc - Preclinical, 2016
GlaxoSmithKline Plc - Discovery, 2016
GlaxoSmithKline Plc - Unknown, 2016
GlaxoSmithKline Plc - Pipeline by Target, 2016
GlaxoSmithKline Plc - Pipeline by Route of Administration, 2016
GlaxoSmithKline Plc - Pipeline by Molecule Type, 2016
GlaxoSmithKline Plc - Pipeline Products by Mechanism of Action, 2016
GlaxoSmithKline Plc - Recent Pipeline Updates, 2016
GlaxoSmithKline Plc - Dormant Developmental Projects,2016
GlaxoSmithKline Plc - Discontinued Pipeline Products, 2016
GlaxoSmithKline Plc, Other Locations
GlaxoSmithKline Plc, Subsidiaries
GlaxoSmithKline Plc, Key Manufacturing Facilities

LIST OF FIGURES

GlaxoSmithKline Plc - Pipeline by Top 10 Indication, 2016
GlaxoSmithKline Plc - Pipeline by Stage of Development, 2016
GlaxoSmithKline Plc - Monotherapy Products in Pipeline, 2016
GlaxoSmithKline Plc - Combination Treatment Modalities in Pipeline, 2016
GlaxoSmithKline Plc - Partnered Products in Pipeline, 2016
GlaxoSmithKline Plc - Out-Licensed Products in Pipeline, 2016
GlaxoSmithKline Plc - Pipeline by Top 10 Target, 2016
GlaxoSmithKline Plc - Pipeline by Route of Administration, 2016
GlaxoSmithKline Plc - Pipeline by Top 10 Molecule Type, 2016
GlaxoSmithKline Plc - Pipeline Products by Top 10 Mechanism of Action, 2016
Skip to top


Ask Your Question

GlaxoSmithKline Plc - Product Pipeline Review - 2016
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: